Please try another search
Name | Net % | Long % | Short % |
---|---|---|---|
Cash | 0.66 | 0.66 | 0.00 |
Shares | 99.34 | 99.34 | 0.00 |
Ratios | Value | Category Average |
---|---|---|
P/E Ratio | 31.67 | 27.95 |
Price to Book | 8.70 | 6.66 |
Price to Sales | 7.06 | 4.16 |
Price to Cash Flow | 22.34 | 18.49 |
Dividend Yield | 0.45 | 0.71 |
5 Years Earnings Growth | 16.82 | 14.79 |
Name | Net % | Category Average |
---|---|---|
Technology | 43.22 | 38.71 |
Communication Services | 13.38 | 11.04 |
Healthcare | 10.87 | 12.87 |
Financial Services | 10.44 | 9.29 |
Consumer Cyclical | 10.27 | 14.19 |
Industrials | 5.28 | 7.18 |
Basic Materials | 4.69 | 1.90 |
Real Estate | 1.14 | 1.69 |
Consumer Defensive | 0.71 | 3.85 |
Number of long holdings: 65
Number of short holdings: 1
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Microsoft Corp | - | 14.03 | - | - | |
NVIDIA Corp | - | 9.17 | - | - | |
Amazon.com Inc | - | 6.73 | - | - | |
Alphabet Inc Class A | - | 5.91 | - | - | |
Meta Platforms Inc Class A | - | 5.58 | - | - | |
Apple Inc | - | 4.53 | - | - | |
Mastercard | US57636Q1040 | 3.79 | 443.61 | +0.57% | |
Visa A | US92826C8394 | 3.05 | 268.47 | +0.32% | |
Eli Lilly | US5324571083 | 2.91 | 735.54 | -2.69% | |
Boston Scientific | US1011371077 | 2.03 | 72.86 | +1.15% |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
MFS Value I | 24.41B | 8.81 | 8.53 | 9.46 | ||
MFS Value R6 | 20.2B | 8.84 | 8.65 | 9.57 | ||
MFS Intl Diversification I | 14.86B | 4.19 | 1.45 | 5.88 | ||
MFS Instl International Equity | 14.7B | 4.74 | 6.55 | 6.83 | ||
MFS Research International R6 | 13.82B | 4.82 | 2.57 | 4.95 |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review